Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer


BACKGROUND Several studies have shown the effectiveness of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for type 2 diabetes, with a hypoglycemic effect being demonstrated both when it is administered alone or in combination with other oral antidiabetic agents. However, there are few reports about its long-term efficacy, although medications for diabetes… (More)
DOI: 10.4021/jocmr1256w


4 Figures and Tables


Citations per Year

Citation Velocity: 10

Averaging 10 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.